APOE Polymorphisms Contribute to Reduced Atorvastatin Response in Chilean Amerindian Subjects
Genetic factors can determine the high variability observed in response to lipid-lowering therapy with statins. Nonetheless, the frequency of single nucleotide polymorphisms (SNPs) and their impact can vary due to ethnicity. Because the Chilean population carries a strong Amerindian background, the...
Main Authors: | Jenny Lagos, Tomás Zambrano, Alexy Rosales, Luis A. Salazar |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2015-04-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/16/4/7890 |
Similar Items
-
SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals
by: Yalena Prado, et al.
Published: (2015-08-01) -
EFFECT OF GENES SLCO1B1 AND MDR1 POLYMORPHISM ON ATORVASTATIN PHARMACOKINETICS AND PHARMACODYNAMICS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: RESULTS OF PILOT PHARMACOGENETICS STUDY
by: A. V. Semenov, et al.
Published: (2016-01-01) -
Pharmacogenetics of OATP Transporters Reveals That SLCO1B1 c.388A>G Variant Is Determinant of Increased Atorvastatin Response
by: Rosario D. C. Hirata, et al.
Published: (2011-09-01) -
ASPECTS OF LIPID-LOWERING THERAPY WITH ATORVASTATIN IN PATIENTS WITH MYOCARDIAL INFARCTION FROM THE PERSPECTIVE OF PERSONALIZED MEDICINE
by: M. V. Solodun, et al.
Published: (2015-09-01) -
Paraoxonase (PON1 and PON3) polymorphisms: impact on liver expression and atorvastatin-lactone hydrolysis
by: Stephan eRiedmaier, et al.
Published: (2011-07-01)